Julphar bolsters management team with new senior appointments
Emirati company Julphar, one of the largest pharmaceutical manufacturers in the Middle East and North Africa (MENA), has announced the appointment of new executives to help guide the company towards profitability and long-term success.
Jerome Carle, chief executive at Julphar said: "We have set forward a new broad reaching strategy that will make us stronger as an organization and help us remain competitive and innovative. A key part of our strategy is ensuring we have the very best people in place.
Manoj Pananchukunnath has been appointed as chief scientific officer. He will oversee the scientific functions of the company and will be tasked with improving efficiency across R&D, Medical Affairs and Regulatory Affairs as well as developing and implementing strategic change. He joins Julphar from Mylan (Nasdaq: MYL), where he was the head of global injectable scientific affairs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze